ArticleOpen medicine (Warsaw, Poland)2021
Identification of ZG16B as a prognostic biomarker in breast cancer.
Article in Open medicine (Warsaw, Poland), 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 27 citations in OpenAlex.
- ZG16B: A key regulator of tumor progression and immune microenvironment modulation in cancer (Review).International journal of molecular medicine · 2026Review
- Decreased salivary ZG16B expression is associated with exocrine dysfunction in Sjögren disease.Clinical rheumatology · 2026Article
- Proteomic Profiling of Pre- and Post-Surgery Saliva of Glioblastoma Patients II: A Preliminary Investigation of the Complementary Low Molecular Mass Fraction.International journal of molecular sciences · 2025Article
- BALs are prognostic biomarkers and correlate with malignant behaviors in breast cancer.BMC cancer · 2025Article
- Zymogen granule protein 16B (ZG16B) is a druggable epigenetic target to modulate the mammary extracellular matrix.Cancer science · 2025Article
- Physics-informed AI with chemical master equation dynamics for driver-gene subclone detection and risk labeling.Computational and structural biotechnology journal · 2025Article
- Unraveling the impact ofIn silico pharmacology · 2025Article
- Unsupervised Random Forest Identifies Important Genetic Prognostic Factors for Breast Cancer Survival Time.Cancer informatics · 2025Article
- Effect of Seminal Plasma on the Freezability of Boar Sperm.Animals : an open access journal from MDPI · 2024Article
- Transcriptomics in idiopathic pulmonary fibrosis unveiled: a new perspective from differentially expressed genes to therapeutic targets.Frontiers in immunology · 2024Article
- Ferroptosis, Metabolic Rewiring, and Endometrial Cancer.International journal of molecular sciences · 2023Review
- FADD as a key molecular player in cancer progression.Molecular medicine (Cambridge, Mass.) · 2022Review
- PredictiveNetwork: predictive gene network estimation with application to gastric cancer drug response-predictive network analysis.BMC bioinformatics · 2022Article
- Shotgun Proteomics for the Identification and Profiling of the Tear Proteome of Keratoconus Patients.Investigative ophthalmology & visual science · 2022Article
- Fully Automated Computational Approach for Precisely Measuring Organelle Acidification with Optical pH Sensors.ACS applied materials & interfaces · 2022Article
- Biogenesis, functions, and clinical implications of circular RNAs in non-small cell lung cancer.Molecular therapy. Nucleic acids · 2022Review
- The regulation of PBXs and their emerging role in cancer.Journal of cellular and molecular medicine · 2022Review
- PAUF as a Target for Treatment of High PAUF-Expressing Ovarian Cancer.Frontiers in pharmacology · 2022Article
- Long Non-Coding RNA in Gastric Cancer: Mechanisms and Clinical Implications for Drug Resistance.Frontiers in oncology · 2022Review
- A six-gene prognostic signature for both adult and pediatric acute myeloid leukemia identified with machine learning.American journal of translational research · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Zymogen granule protein 16B (ZG16B) has been identified in various cancers, while so far the association between ZG16B and breast cancer hasn't been explored. Our aim is to confirm whether it can serve as a prognostic biomarker in breast cancer. In this study, Oncomine, Cancer Cell Line Encyclopedia (CCLE), Ualcan, and STRING database analyses were conducted to detect the expression level of ZG16B in breast cancer with different types. Kaplan-Meier plotter was used to analyze the prognosis of patients with high or low expression of ZG16B. We found that ZG16B was significantly upregulated in breast cancer. Moreover, ZG16B was closely associated with foregone biomarkers and crucial factors in breast cancer. In the survival analysis, high expression of ZG16B represents a favorable prognosis in patients. Our work demonstrates the latent capacity of ZG16B to be a biomarker for prognosis of breast cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.